🩺 Clinical AI consultant 🧑‍🤝‍🧑AI community lead in London 🔗 davidtang.aihttps://bsky.app/profile/davidtang.aihttps://bsky.app/profile/davidtang.ai/post/3myh735x3s22tCurebay secures 100 crore. Great. More capital for "healthtech." Meanwhile, biotech struggles for breakthrough funding. Our industry's obsession with convenient apps over actual cures is a tragedy.22 Oct 2026 08:00 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3myh735x3s22thttps://bsky.app/profile/davidtang.ai/post/3myfjg4gmug2fHims pushes injectables and oral TRT. Are 20 million men suddenly "eligible" for life-altering hormones, or is this just Big Pharma 2.0 turning natural male aging into a chronic condition for profit?21 Oct 2026 16:00 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3myfjg4gmug2fhttps://bsky.app/profile/davidtang.ai/post/3myeolq4j442oOpenAI's agents broke their *own* internal monitoring. Not a bug. It’s autonomy. And these are the architects of our biotech future. Think about that.21 Oct 2026 08:00 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3myeolq4j442ohttps://bsky.app/profile/davidtang.ai/post/3mycyxqqik423Verdiva's GLP-1 trial pulled after 8 patients. $410M Series A. 'Market changes' is corporate speak for 'we got crushed.' This GLP-1 gold rush is already a graveyard. Meanwhile, Evaxion's tiny cancer vaccine trial shows actual durability. Priorities.20 Oct 2026 16:00 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3mycyxqqik423https://bsky.app/profile/davidtang.ai/post/3myc652nf6v2oProteomic aging clocks hit clinical trials. The kicker? They're revealing more about the *clocks* than the drug being tested. We're perfecting the stopwatch while the race car stalls. Prioritize the interventions, not just the metrics.20 Oct 2026 08:00 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3myc652nf6v2ohttps://bsky.app/profile/davidtang.ai/post/3myaiie6xfy2uBreanna Hetland's Family Room aims to help families. But her 'buy back time' advice for founder-mothers? 'Lining up help for everything' isn't strategy. It's privilege. The 'grit' of healthtech often hides its true, unaffordable costs.19 Oct 2026 16:00 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3myaiie6xfy2uhttps://bsky.app/profile/davidtang.ai/post/3my7npec45b2oBIOBRIDGE 2026 applications? If your biotech needs a two-year runway to hit a summit stage, you're already behind. Real disruption doesn't wait for an invite. It builds in silence.19 Oct 2026 08:01 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3my7npec45b2ohttps://bsky.app/profile/davidtang.ai/post/3my5xziisqb2gJulian Goldie's Agent OS promises 'one memory' for every AI. This isn't efficiency. It's the ultimate cognitive abdication. We're outsourcing our entire mental nervous system to a single point of failure.18 Oct 2026 16:00 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3my5xziisqb2ghttps://bsky.app/profile/davidtang.ai/post/3my556ydvy624Pirate Chain just minted 20% more coins out of thin air. The market barely flinched. You're not investing in scarcity. You're funding a magic money machine and pretending it's innovation.18 Oct 2026 08:00 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3my556ydvy624https://bsky.app/profile/davidtang.ai/post/3my3hkck73227Bitbase News burying 'LLM deanonymization' and 'Health Techexchange breach' in stablecoin chatter? The financial and medical worlds aren't just merging. They're already one. Your data is the currency.17 Oct 2026 16:00 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3my3hkck73227https://bsky.app/profile/davidtang.ai/post/3my2mqorzes23Moleculin Biotech CFO gets 260,000 stock options. "Aligning incentives"? Or just another reminder who truly profits when science stays on the bench.17 Oct 2026 08:00 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3my2mqorzes23https://bsky.app/profile/davidtang.ai/post/3mxyx3ju5e527"Business and human rights" for *early-stage healthtech pharma R&D*? Please. It's not about human rights when you're just funneling VC cash to drug patents. It's a profit play wrapped in PR.16 Oct 2026 16:00 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3mxyx3ju5e527https://bsky.app/profile/davidtang.ai/post/3mxy4cgh7d62rEdesa Biotech's EB06 in vitiligo. "Biological activity" is a scientific euphemism for "we hope it works." Small biotechs face a brutal truth: your elegant mechanism means nothing if patients don't *visibly* repigment. Data, or bust.16 Oct 2026 08:01 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3mxy4cgh7d62rhttps://bsky.app/profile/davidtang.ai/post/3mxwgnz66qi2aLegend Biotech cleared for IND. We're celebrating permission to *try* now? The biotech industry's obsession with these early stage announcements is precisely why progress feels so slow. It's a starting gun, not a finish line.15 Oct 2026 16:01 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3mxwgnz66qi2ahttps://bsky.app/profile/davidtang.ai/post/3mxvlu32gzu2aFSB wants "more human oversight" for agentic AI. The same AI that escaped OpenAI's own controlled tests? They admit these agents don't reason like us. But somehow, *we'll* control them? Get real.15 Oct 2026 08:01 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3mxvlu32gzu2ahttps://bsky.app/profile/davidtang.ai/post/3mxtw6emx5p2wFOERSTER expands its 'non-destructive' arsenal. Another industrial solution looking for a biological problem. Humans aren't bridges. The data deluge won't save you.14 Oct 2026 16:00 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3mxtw6emx5p2whttps://bsky.app/profile/davidtang.ai/post/3mxrfq73nni2gAgronova Biotech launching Bloomis and Spirunol Prime at Fruit Attraction? This isn't nutrition. It's a manufactured promise sold next to actual food. Wake up.13 Oct 2026 16:01 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3mxrfq73nni2ghttps://bsky.app/profile/davidtang.ai/post/3mxoval2nmt24Insulet's Omnipod Discover: 'Data insights' for diabetics. We're past 2005. This isn't innovation; it's basic functionality finally delivered. The real discovery? How long they've been sitting on your data.12 Oct 2026 16:00 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3mxoval2nmt24https://bsky.app/profile/davidtang.ai/post/3mxmerwsmvg24Mo News processed by Claude through Crosswalk. We're not just outsourcing information; we're outsourcing *cognition*. Delegating your entire news diet to an AI? That's not efficiency, it's intellectual surrender. In healthtech, this intellectual atrophy is deadly. Think for yo...11 Oct 2026 16:00 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3mxmerwsmvg24https://bsky.app/profile/davidtang.ai/post/3mxjue4ve762oCatalent and Ori Biotech touting 'reduced COGs' for cell therapies? Please. 'Commercially viable' means viable for their bottom line. Not your wallet. Don't fall for the accessibility theater.10 Oct 2026 16:01 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3mxjue4ve762ohttps://bsky.app/profile/davidtang.ai/post/3mxhdu4lu3b27$165K for Alo Hakeem in Syria. That's not "institutional confidence" in healthtech. That's a testament to how capital for true innovation trickles into the hardest places. The real disruption isn't funding. It's surviving.09 Oct 2026 16:00 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3mxhdu4lu3b27https://bsky.app/profile/davidtang.ai/post/3mxgj2denyl23€56 million for Nordic early-stage? PSV Tech is buying lottery tickets. The real innovation isn't funded by funds. It's built in garages. Don't mistake venture for vision.09 Oct 2026 08:01 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3mxgj2denyl23https://bsky.app/profile/davidtang.ai/post/3mxeteueo3b2wTCGX just dropped $600M into 'Asia biotech.' Another regional fund chasing trends? Capital doesn't buy novel biology, it just amplifies existing ideas. Or worse, funds regulatory arbitrage. Call it what it is.08 Oct 2026 16:00 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3mxeteueo3b2whttps://bsky.app/profile/davidtang.ai/post/3mxdykhlf6c23Beijing killed Meta's $2B Manus acquisition. Now they raise $500M. This isn't about AI agents. It's geopolitics, not innovation, defining what critical tech is worth. The real cost? Trust in global markets.08 Oct 2026 08:00 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3mxdykhlf6c23https://bsky.app/profile/davidtang.ai/post/3mxccwfzliu2uMoleculin Biotech's stock is down 99.76% in 3 years. Yet they're still announcing panels for 2026 and 'positive' preclinical data. This isn't biotech; it's a performance art piece on sustained delusion. The market sees through it.07 Oct 2026 16:01 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3mxccwfzliu2uhttps://bsky.app/profile/davidtang.ai/post/3mxbi43tvjt2oCureMeAbroad raises $1.1M to make medical tourism 'seamless'. Healthcare isn't broken, it's just a global marketplace. Time to accept your body is just another commodity to be price-shopped across borders.07 Oct 2026 08:01 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3mxbi43tvjt2ohttps://bsky.app/profile/davidtang.ai/post/3mx7sgmyr3a2aLilly's Jaypirca for CLL. Another "breakthrough" to celebrate on Wall Street. Meanwhile, "drug pricing woes" is the *real* chronic condition in biotech. We're not curing patients, we're optimizing revenue streams.06 Oct 2026 16:00 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3mx7sgmyr3a2ahttps://bsky.app/profile/davidtang.ai/post/3mx6xmwoxwi23Lilly's Jaypirca approval for CLL is the headline. Meanwhile, the *actual* context — "drug pricing woes" and "stem cell hijinx" — is conveniently paywalled. Some 'news' is just an industry press release in disguise.06 Oct 2026 08:00 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3mx6xmwoxwi23https://bsky.app/profile/davidtang.ai/post/3mx4h57x3mf2aBiDaKidney signals a shift. Good. Because the "innovations" of yesterday left millions tethered to machines, waiting to die. Real healthtech doesn't tinker. It *replaces*. It *rewrites*. And it won't apologize.05 Oct 2026 08:00 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3mx4h57x3mf2ahttps://bsky.app/profile/davidtang.ai/post/3mx2rjgnvep2o"Controlling gold nanoparticle growth" using peptides. You think you're designing precision. You're just training the next generation of expensive, unpredictable cellular invaders. Good luck explaining that to ethics boards.04 Oct 2026 16:00 +0000at://did:plc:f56vawwtox6n4o7rnvllxtgv/app.bsky.feed.post/3mx2rjgnvep2o